Breast cancer
Conditions
Interventions
Observation group:None
Sponsors
Sun Yat-sen University Cancer Center
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Sign the informed consent form for participation in the clinical study. 2. Patients with histologically confirmed triple-negative breast invasive carcinoma (patients with ER/PR 1%-10% positivity and HER2 negativity can also be included due to biological characteristics similar to triple-negative breast cancer); 3. Clinical staging: T2-3N0-3M0; T1N1-3M0; 4. Female patients aged 18 to 70; 5. No history of previous malignant tumors; 6. Eligible patients plan to receive standard neoadjuvant chemotherapy combined with immunotherapy followed by surgery; patients who are ready to receive or have completed standard neoadjuvant chemotherapy combined with immunotherapy awaiting surgery are also considered eligible. 7. Pathological neoadjuvant chemotherapy combined immunotherapy response (pCR or non-pCR) needs to be confirmed. 8. MRI and core needle biopsy are both acceptable; perform MRI and biopsy within 2 weeks before neoadjuvant chemotherapy combined with immunotherapy. 9. Perform MRI after two cycles of neoadjuvant chemotherapy combined with immunotherapy. 10. No other tumors occur during neoadjuvant chemotherapy combined with immunotherapy and surgery.
Exclusion criteria
Exclusion criteria: 1. History of previous chemotherapy, endocrine therapy, anti-HER2 biological therapy, immunotherapy, or radiotherapy; 2. History of previous malignant tumors; 3. History of autoimmune diseases, including systemic lupus erythematosus, scleroderma, etc.; 4. History of definite neurological or psychiatric disorders, including epilepsy or dementia; 5. Patients who received non-standard treatment or did not complete the neoadjuvant chemotherapy combined with immunotherapy regimen; 6. No surgery performed or incomplete postoperative pathological results; 7. Lack of clinical information, MRI images, or biopsy pathology results required for analysis; 8. Poor quality of MRI images; 9. Other reasons deemed unsuitable for inclusion by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| accuracy;Specificity;Area under the curve; | — |
Countries
China
Contacts
Public ContactJun Tang
Sun Yat-sen University Cancer Center
Outcome results
None listed